Castle Biosciences Inc (CSTL) income statement
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/302% below fair value
$33.38+0.40 (+1.21%)
Close on Nov 18, 2026Market cap $1.02BP/E –Yield 0.00%
Castle Biosciences Inc income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 77.1%
- Operating margin
- -7.4%
- Net margin
- -6.1%
- Return on equity, FY2025
- -5.2%
Financial strength
- Current ratio
- 5.28
- Debt to equity
- 0.02
- Debt to assets
- 1.7%
- Cash to current liabilities
- 115.4%
Valuation
- P/E ratio
- –
- Price to sales
- 2.70
- Price to book
- 2.13
- Dividend yield
- 0.00%
See a number that looks wrong?